Eli Lilly and Company partnered with DKSH Business Unit Healthcare to distribute pharmaceutical products in Hong Kong and Macau. This agreement expands on existing collaborations in Singapore and Vietnam to improve regional patient access.
Cantor Fitzgerald raised its price target for Eli Lilly shares to $1,350 from $1,230. The firm maintained an Overweight rating citing expectations for strong second-quarter results. Analysts believe sector-wide performance will lead to upward revisions in fiscal year guidance.